Skip to main content

RheumNow Podcast – Better Ways to Treat Gout (11.8.19)

Dr. Jack Cush reviews the news and journal articles from the past week on

  1. Study of ANA+ people without lupus or CTD shows that fatigue does not increase odds of having lupus or CTD. 1/3 of ANA referrals had FM and fatigue was correlated with widespread pain.
  2. Methotrexate - an old drug with new tricks! new publication reviews the use of MTX in the management of chronic viral arthritis, including chikungunya and other old world alphaviruses, Parvovirus B19, hepatitis B/C virus, and human immunodeficiency virus
  3. Retrospective study from Spanish SLE register RELESSER: in 3539 SLE patients, the risk of cancer was elevated (SIR=1.37; CI 95%: 1.15‐1.59), higher in women (SIR=2.38). SLICC Dz activity and ACE inhibitor use was assoc w/ non-Hormone sensitive CA
  4. Cancer Risk with psoriasis? Metanalysis of 58 studies shows that PSO is associated with an 18-22% increased risk of all cancers, highest w/ severe PSO. Increased risk of colon, laryngeal, liver, lymphoma/NHL, esophageal, oral cavity & pancreatic CA
  5. CONTACT trial compared colchicine 0.5 mg tid vs naproxen 250 mg tid in treating 399 patients with acute #gout. Both drugs equally controlled patient pain, but had more diarrhea (46% vs 20%) and headache (20.5% vs 10.7%) in first 7 days. 
  6. Analysis of 92 #Gout pts treated with pegloticase compared pre-Rx prophylaxis with IV hydrocortisone or methylprednisolone (MP), finds that IV MP had more PEG infusions (8.5 vs 4.9) & fewer infusion reactions (8% vs 42%) compared with IV hydrocortisone
  7. T2T Lowers Mortality in Gout     
  8. New EMA Warnings for Tofacitinib in Patients at Risk for Clots   
  9. EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis   
  10. Rinvoq (upadacitinib) Effective in Psoriatic Arthritis 


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has received compensation as an advisor or consultant on this subject